Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1939 Target Snapshot

Bifunctional dihydrofolate reductase-thymidylate synthase · SINGLE PROTEIN · Plasmodium falciparum K1

Back to Search Search this target Browse approvals Evidence Card
229Compounds
116Assays
6Approved Drugs
1,122.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Bifunctional dihydrofolate reductase-thymidylate synthase shows approved-linked disease relevance led by malaria. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P13922. Start with malaria, then reuse UniProt P13922 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with malaria, then reuse UniProt P13922 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 3 linked drugs
Open source guide
Disease program
malaria

Bifunctional dihydrofolate reductase-thymidylate synthase shows approved-linked disease relevance led by malaria. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with malaria because it currently carries approved-linked support. Linked drugs include CYCLOGUANIL PAMOATE, PROGUANIL HYDROCHLORIDE, PYRIMETHAMINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Bifunctional dihydrofolate reductase-thymidylate synthase as ChEMBL target CHEMBL1939, mapped to UniProt P13922. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Bifunctional dihydrofolate reductase-thymidylate synthase
SINGLE PROTEIN · Plasmodium falciparum K1
As of 2026-09-13
ChEMBL target ID
CHEMBL1939
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P13922
Bifunctional dihydrofolate reductase-thymidylate synthase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Bifunctional dihydrofolate reductase-thymidylate synthase is the right protein anchor across sources, using UniProt P13922 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why malaria is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameBifunctional dihydrofolate reductase-thymidylate synthase
Target TypeSINGLE PROTEIN
OrganismPlasmodium falciparum K1
UniProtP13922
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelBifunctional dihydrofolate reductase-thymidylate synthase
UniProt AccessionP13922
Component TypeProtein
Sequence Length608 aa

Bifunctional dihydrofolate reductase-thymidylate synthase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Bifunctional dihydrofolate reductase-thymidylate synthase, mapped to UniProt P13922. Sequence length is 608 aa.

Mapped IDP13922
Review nameBifunctional dihydrofolate reductase-thymidylate synthase
OrganismPlasmodium falciparum K1
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Bifunctional dihydrofolate reductase-thymidylate synthase shows approved-linked disease relevance led by malaria. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
malaria
3 linked drugs · 3 direct · 3 efficacy
Linked drugCYCLOGUANIL PAMOATE
Linked drugPROGUANIL HYDROCHLORIDE
Linked drugPYRIMETHAMINE
Approved-linked Approved
toxoplasmosis
1 linked drug · 1 direct · 1 efficacy
Linked drugPYRIMETHAMINE
Late clinical Phase III
anemia (phenotype)
1 linked drug · 1 direct · 1 efficacy
Linked drugPYRIMETHAMINE
Late clinical Phase III
Chorioretinitis
1 linked drug · 1 direct · 1 efficacy
Linked drugPYRIMETHAMINE
Late clinical Phase III
congenital toxoplasmosis
1 linked drug · 1 direct · 1 efficacy
Linked drugPYRIMETHAMINE
Late clinical Phase III
depressive disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugPYRIMETHAMINE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with malaria because it currently carries approved-linked support. Linked drugs include CYCLOGUANIL PAMOATE, PROGUANIL HYDROCHLORIDE, PYRIMETHAMINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasemalaria
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

6
Approved
3
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC50379.0
KI739.0
KD4.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1201746 10.87 Ki 0.0134 Approved
CHEMBL22405 9.85 Ki 0.14 Preclinical
CHEMBL5598041 9.8 Ki 0.16 Preclinical
CHEMBL36 9.72 Ki 0.19 Approved
CHEMBL5415214 9.68 Ki 0.21 Preclinical
CHEMBL5397904 9.64 Ki 0.23 Preclinical
CHEMBL5597152 9.62 Ki 0.24 Preclinical
CHEMBL5596188 9.62 Ki 0.24 Preclinical
CHEMBL5597998 9.6 Ki 0.25 Preclinical
CHEMBL5421199 9.6 Ki 0.25 Preclinical
Distribution

pChEMBL Value Distribution

114
5.0
109
5.5
96
6.0
124
6.5
112
7.0
88
7.5
106
8.0
124
8.5
74
9.0
22
9.5
pChEMBL
Approved Drugs

Approved Drugs

PRALATREXATE
CHEMBL1201746
Approved 2009
Properties Compare Identifier
TRIMETHOPRIM
CHEMBL22
Approved 1973
Properties Compare Identifier
PYRIMETHAMINE
CHEMBL36
Approved 1953
Properties Compare Identifier
METHOTREXATE
CHEMBL34259
Approved 1953
Properties Compare Identifier
Assay Landscape

Assay Landscape

116
Total Assays
193
Tested Compounds
2
Assay Types
Binding — 99 assays, 193 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 98 185 7.4
cell-based format 1 8 9.5
Functional — 17 assays, 70 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 17 70 5.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine